Every 424B that CapsoVision, Inc. (CV) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow CV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CV filings page.
CapsoVision, Inc. (CV) is conducting a primary offering of 3,163,444 shares of common stock at $5.69 per share to existing investors under a shelf registration, for gross proceeds of about $18.0 million and estimated net proceeds of about $17.8 million after expenses. The price reflects a discount of approximately 5% to the $5.99 last reported sale price on The Nasdaq Capital Market on September 16, 2026, and no underwriter or placement agent is involved, so no underwriting discounts or commissions are being paid.
Shares outstanding will increase from 50,032,148 as of June 30, 2026 to 53,195,592 after the offering, excluding warrants, options, RSUs, plan reserves and recent ATM issuances. The company plans to use the proceeds for general corporate purposes, including sales and marketing, research and development, general and administrative expenses, and working capital, with interim investment in money market funds.
CapsoVision is a commercial-stage medical technology company focused on GI-tract capsule endoscopy, deriving most of its revenue from its FDA-cleared CapsoCam Plus capsule. Revenue from CapsoCam Plus was approximately $6.4 million for the six months ended June 30, 2026 versus $6.1 million a year earlier, and $13.6 million for 2025 versus $11.8 million for 2024. The company highlights pipeline efforts including AI-assisted CapsoCam Plus, a second-generation CapsoCam Colon capsule, and early-stage pancreatic cancer and esophageal indications, while cautioning that regulatory clearances and clinical results are uncertain.
CapsoVision, Inc. (CV) has established an at-the-market equity offering program under a Form S-3 shelf, allowing it to sell up to $100,000,000 of common stock from time to time through Cantor Fitzgerald & Co. as sales agent or principal. Sales will be made on The Nasdaq Capital Market or other permitted methods deemed an “at the market offering” under Rule 415(a)(4).
Cantor will use commercially reasonable efforts and receive up to 3.0% of aggregate gross proceeds as commissions, and will be deemed an underwriter. Assuming an illustrative price of $6.86 per share (the August 12, 2026 last sale price) and full utilization, CapsoVision would sell approximately 14,577,259 shares, resulting in up to 64,609,407 shares outstanding. Net tangible book value would increase from $0.26 to $1.70 per share, implying dilution of $5.16 per share to new investors at that price.
The company intends to use any net proceeds for general corporate purposes, including sales and marketing, research and development, general and administrative expenses, and working capital, with interim investment in money market funds. The filing highlights that investing involves a high degree of risk, including potential volatility, future capital needs, and possible additional dilution from outstanding warrants, options, restricted stock units, and future equity issuances.
CapsoVision, Inc. is registering for resale up to 2,867,089 shares of common stock that were issued in a private placement (the “PIPE Shares”) under the Securities Purchase Agreement dated March 16, 2026.
The registration is being made pursuant to the Registration Rights Agreement dated March 16, 2026 and the selling stockholders will receive all proceeds from any resales; the company will receive no resale proceeds but will pay registration expenses.